SGRY

Surgery Partners, Inc. (SGRY) - Q3 2024 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended September 30, 2024. Surgery Partners, Inc. owns and operates a national network of surgical facilities, including 147 ambulatory surgery centers (ASCs) and 19 surgical hospitals across 33 states. As of the reporting date, the Company consolidated 123 facilities for financial reporting purposes. The Company operates primarily in partnership with physicians and healthcare systems.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Q3 2024 revenue increased 14.3% year-over-year, driven by a 4.2% increase in days-adjusted same-facility revenue (due to a 3.7% increase in case volume and 0.5% increase in revenue per case) and the net impact of acquisitions.
• Profitability: While Adjusted EBITDA grew 21.9% to $128.6 million, GAAP operating income declined to $60.9 million from $82.6 million. This was primarily due to a significant increase in transaction and integration costs ($29.4 million vs. $12.8 million) and depreciation/amortization ($50.2 million vs. $28.9 million).
• Net Loss: The net loss attributable to Surgery Partners, Inc. widened significantly to $31.7 million from $4.9 million, largely due to higher non-controlling interest allocations ($38.1 million vs. $34.6 million) and increased transaction costs.
• Debt Restructuring: The Company issued $800 million in 7.25% senior unsecured notes due 2032 to redeem existing 2025 and 2027 notes. Additionally, the Company refinanced its term loans with $1.4 billion in new 2024 Refinancing Term Loans maturing in 2030.
• Acquisitions: Net cash used for acquisitions was $291.2 million in the first nine months of 2024, compared to $48.8 million in the prior year period.

Outlook, Risks, and Unusual Items

• Management Commentary: Management continues to focus on same-facility performance, selective acquisitions, and de novo development. They believe current cash flows, available cash, and revolver capacity are adequate for short and long-term liquidity needs.
• Unusual Items:
  • Hurricane Helene: The Company incurred hurricane-related impacts in Q3 2024, affecting collections and operations.
  • Transaction Costs: Significant transaction and integration costs ($66.1 million YTD) and a $5.1 million loss on debt extinguishment impacted YTD results.
  • Disposals: The Company recognized a net loss of $21.5 million on disposals, consolidations, and deconsolidations YTD 2024.
• Risks: Key risks include changes in government and private payor reimbursement rates, regulatory changes (e.g., Florida laws on letters of protection), interest rate volatility, and the ability to integrate acquired facilities. The Company maintains interest rate swaps and caps to manage exposure to variable rate debt.

Investor Verification Checklist

• Verify the sustainability of the 4.2% same-facility revenue growth rate given the mix of high-acuity procedures.
• Monitor the impact of the new $1.4 billion term loan and $800 million note issuance on future interest expense and debt covenants.
• Assess the trajectory of transaction and integration costs, which are currently elevated due to active M&A.
• Review the specific financial impact of Hurricane Helene on collections and operating expenses in subsequent quarters.
• Confirm the Company's ability to maintain Adjusted EBITDA growth while managing the widening GAAP net loss attributable to common stockholders.